We are live on ! Find out more
ALXO icon

ALX Oncology

108 hedge funds and large institutions have $144M invested in ALX Oncology in 2026 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

13,700% more call options, than puts

Call options by funds: $138K | Put options by funds: $1K

425% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 4

16% more funds holding

Funds holding: 93 → 108 (+15)

13% more capital inflows, than outflows

Capital inflows: $21.5M | Capital outflows: $19M

0% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 32

3.12% less ownership

Funds ownership: 78.17% → 75.05% (-3.1%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
108
Holders Change
+15
Holders Change %
+16.13%
% of All Funds
1.33%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
21
Increased
32
Reduced
32
Closed
4
Calls
$138K
Puts
$1K
Net Calls
+$137K
Net Calls Change
-$44K

ALXO Hedge Fund Activity: Q3 2026 in Review

108 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q3 2026, worth a combined $144M — down 34% from $218M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ALXO positions and 4 closed out — a net gain of 17 holders — while 32 added to existing stakes and 32 trimmed.

The largest buyer was Squadron Capital Management, opening a new position worth an estimated $2.7M. The largest seller was Vivo Capital, exiting entirely with an estimated $6.59M sold.

  • 108 institutional investors held ALX Oncology (ALXO) as of Q3 2026, up from 93 in Q2 2026.
  • Funds reported $144M of ALX Oncology stock for Q3 2026, down 34% quarter-over-quarter.
  • 21 funds opened new ALX Oncology positions in Q3 2026 and 4 closed out, a net change of +17 holders.
  • The largest ALX Oncology buyer in Q3 2026 was Squadron Capital Management, an estimated $2.7M added.
  • The largest ALX Oncology seller in Q3 2026 was Vivo Capital, an estimated $6.59M sold.

Based on aggregated 13F filings for Q3 2026.